Treadmill endurance during 2-year treatment with tiotropium in patients with COPD: A randomized trial

Chest

Volumn 144, Issue 2, 2013, Pages 490-497

  Cooper, Christopher B ^a   Celli, Bartolome R ^b   Jardim, José R ^c   Wise, Robert A ^d   Legg, Daniel ^e   Guo, Junhai ^e   Kesten, Steven ^f  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

^f Cytori Therapeutics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LONG ACTING DRUG; PLACEBO; SHORT ACTING DRUG; STEROID; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ANTICHOLINERGIC EFFECT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; ENDURANCE TRAINING; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; HYPOTENSION; INHALER; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OUTCOME ASSESSMENT; PARALLEL DESIGN; PHYSICAL PERFORMANCE; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; SCORING SYSTEM; SIDE EFFECT; SMOKING; SPIROMETRY; ST. GEORGE RESPIRATORY QUESTIONNAIRE; TREADMILL ENDURANCE TIME; TREADMILL EXERCISE; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 84881534452     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.12-2613     Document Type: Article

References (32)

1. Cooper CB. Exercise in chronic pulmonary disease: limitations and rehabilitation. Med Sci Sports Exerc. 2001; 33 (suppl 7): S643-S646.
2. Global strategy for the diagnosis, management, and prevention of COPD, Global Initiative for Chronic Obstructive Lung. Dis ease (GOLD) 2013. GOLD website. http://www.goldcopd. org. Accessed September 24, 2010.
3. Maltais F, Hamilton A, Marciniuk D, et al. Improvements in symptom-limited exercise performance over 8 h with oncedaily tiotropium in patients with COPD. Chest. 2005; 128 (3): 1168-1178.
4. O'Donnell DE, Flüge T, Gerken F, et al. Effects of tiotropium on lung hyperinfl ation, dyspnoea and exercise tolerance in COPD. Eur Respir J. 2004; 23 (6): 832-840.
5. Casaburi R, Kukafka D, Cooper CB, Witek TJ Jr, Kesten S. Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest. 2005; 127 (3): 809-817.
6. Cooper CB, Abrazado M, Legg D, Kesten S. Development and implementation of treadmill exercise testing protocols in COPD. Int J Chronic Obstruct Pulmon Dis. 2010; 5: 375-385.
7. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med. 1999; 159 (1): 179-187.
8. Porszasz J, Casaburi R, Somfay A, Woodhouse LJ, Whipp BJ. A treadmill ramp protocol using simultaneous changes in speed and grade. Med Sci Sports Exerc. 2003; 35 (9): 1596-1603.
9. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 1999; 160 (2): 542-549.
10. Casaburi R. Factors determining constant work rate exercise tolerance in COPD and their role in dictating the minimal clinically important difference in response to interventions. COPD. 2005; 2 (1): 131-136.
11. Ferguson C, Rossiter HB, Whipp BJ, Cathcart AJ, Murgatroyd SR, Ward SA. Effect of recovery duration from prior exhaustive exercise on the parameters of the power-duration relationship. J Appl Physiol. 2010; 108 (4): 866-874.
12. Neder JA, Jones PW, Nery LE, Whipp BJ. Determinants of the exercise endurance capacity in patients with chronic obstructive pulmonary disease. The power-duration relationship. Am J Respir Crit Care Med. 2000; 162 (2 pt 1): 497-504.
13. Morgan MD, Singh SJ. Assessing the exercise response to a bronchodilator in COPD: time to get off your bike? Thorax. 2007; 62 (4): 281-283.
14. Zhang X, Waterman LA, Ward J, Baird JC, Mahler DA. Advantages of endurance treadmill walking compared with cycling to assess bronchodilator therapy. Chest. 2010; 137(6): 1354-1361.
15. Oga T, Nishimura K, Tsukino M, Hajiro T, Ikeda A, Izumi T. The effects of oxitropium bromide on exercise performance in patients with stable chronic obstructive pulmonary disease. A comparison of three different exercise tests. Am J Respir Crit Care Med. 2000; 161 (6): 1897-1901.
16. Puente-Maestu L, Villar F, de Miguel J, et al. Clinical relevance of constant power exercise duration changes in COPD. Eur Respir J. 2009; 34 (2): 340-345.
17. Holland AE, Hill CJ, Rasekaba T, Lee A, Naughton MT, McDonald CF. Updating the minimal important difference for six-minute walk distance in patients with chronic obstructive pulmonary disease. Arch Phys Med Rehabil. 2010; 91(2): 221-225.
18. Puhan MA, Mador MJ, Held U, Goldstein R, Guyatt GH, Schünemann HJ. Interpretation of treatment changes in 6-minute walk distance in patients with COPD. Eur Respir J. 2008; 32 (3): 637-643.
19. Redelmeier DA, Bayoumi AM, Goldstein RS, Guyatt GH. Interpreting small differences in functional status: the six minute walk test in chronic lung disease patients. Am J Respir Crit Care Med. 1997; 155 (4): 1278-1282.
20. Calverley PM, Spencer S, Willits L, Burge PS, Jones PW; IOSLDE Study Group. Withdrawal from treatment as an outcome in the ISOLDE study of COPD. Chest. 2003; 124 (4): 1350-1356.
21. Vestbo J, Anderson JA, Calverley PM, et al. Bias due to withdrawal in long-term randomised trials in COPD: evidence from the TORCH study. Clin Respir J. 2011; 5 (1): 44-49.
22. Kesten S, Plautz M, Piquette CA, Habib MP, Niewoehner DE. Premature discontinuation of patients: a potential bias in COPD clinical trials. Eur Respir J. 2007; 30 (5): 898-906.
23. Decramer M, Lacquet LM, Fagard R, Rogiers P. Corticosteroids contribute to muscle weakness in chronic airfl ow obstruction. Am J Respir Crit Care Med. 1994; 150 (1): 11-16.
24. Roberts CM, Bell J, Wedzicha JA. Comparison of the effi cacy of a demand oxygen delivery system with continuous low fl ow oxygen in subjects with stable COPD and severe oxygen desaturation on walking. Thorax. 1996; 51 (8): 831-834.
25. American Association of Cardiovascular and Pulmonary Rehabilitation. AACVPR Guidelines for Pulmonary Rehabilitation Programs. 3rd ed. Champaign, IL: Human Kinetics; 2004.
26. Ries AL, Bauldoff GS, Carlin BW, et al. Pulmonary rehabilitation: joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest. 2007 ;131(suppl 5):4S-42S.
27. O'Donnell DE, Casaburi R, Vincken W, et al; INABLE 1 study group. Effect of indacaterol on exercise endurance and lung hyperinfl ation in COPD. Respir Med. 2011; 105 (7): 1030-1036.
28. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T, Mishima M. Exercise capacity deterioration in patients with COPD: longitudinal evaluation over 5 years. Chest. 2005; 128 (1): 62-69.
29. Casanova C, Cote CG, Marin JM, et al. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J. 2007; 29 (3): 535-540.
30. Tashkin DP, Celli B, Senn S, et al; for the UPLIFT Study Investigators. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008; 359: 1543-1554.
31. Cooper CB. The connection between chronic obstructive pulmonary disease symptoms and hyperinfl ation and its impact on exercise and function. Am J Med. 2006; 119 (10)(suppl 1): 21-31.
32. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002; 19 (2): 217-224.